Wedbush Maintains Neutral on Nektar Therapeutics, Lowers Price Target to $50

Benzinga Newsdesk www.benzinga.com Negative 50.9%

Neg 50.9% Neu 0% Pos 0%

Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and lowers the price target from $80 to $50.